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Abstract
Background: Clinical trials oversight by a Trial Steering Committee (TSC) is mandated by Good Clinical Practice.
This study used qualitative methods to explore the role and valued attributes of the TSC to inform planned updates
of Medical Research Council guidance and TSC terms of reference.
Methods: An ethnographic study was conducted during 2013–2014. TSC and Trial Management Group meetings
from eight trials were observed and audio-recorded, and semi-structured interviews conducted with purposively
sampled key informants: independent and non-independent TSC members, trial sponsor representatives, funder
representatives and chief investigators. The selected trials were currently recruiting and dealing with challenging
scenarios. Data were analysed thematically and findings triangulated and integrated to give a multi-perspective
account of the role and valued attributes of a TSC.
Results: Eight TSC meetings and six Trial Management Group meetings were observed. Sixty-five interviews were
conducted with 51 informants. The two main roles played by the TSC were quality assurance and patient advocacy.
Quality assurance involved being a ‘critical friend’ or a provider of ‘tough love’. Factors influencing the ability of the
TSC to fulfil this role included the TSC Chair, other independent TSC members and the model of the TSC and its fit
with the trial subject. The role of the TSC as an advocate for patient well-being was perceived as paramount. Two
attributes of TSC members emerged as critical: experience (of running a trial, trial oversight or in a
clinical/methodological area) and independence. While independence was valued for giving impartiality, the lack of
consensus about its definition and strict requirements of some funders made it difficult to operationalise.
Conclusions: We found tensions and ambiguities in the roles expected of TSCs and the attributes valued of TSC
members. In particular, the requirements of independence and experience could conflict, impacting the TSCs’ quality
assurance role. Concerns were raised regarding whose interests are served by funders’ criteria of independence; in
particular, funders’ selection of TSC members was thought to potentially inhibit TSCs’ ability to fulfil their patient
advocacy role. These findings should be incorporated in revising guidance and terms of reference for TSCs.
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Background
Good oversight of late-phase randomised controlled tri-
als (RCTs) is part of the quality assurance process. While
there is acknowledged variation in oversight practice
within the UK and internationally [1], the UK Medical
Research Council (MRC) Guidelines for Good Clinical
Practice (1998) recommend that trial oversight should
include an element of expert advice that is independent
of the Chief Investigator (CI) and host institution in-
volved [2]. This oversight is usually provided by a Trial
Steering Committee (TSC).
In the tripartite trial oversight structure recom-
mended by the MRC, the role of the TSC is to act as
an executive body providing overall supervision of the
trial [2]. The TSC considers the recommendations
made by the Data Monitoring Committee (DMC),
which reviews safety and efficacy data and steers the
Trial Management Group (TMG) responsible for the
day-to-day delivery and conduct of the trial. TSCs are
expected to monitor and supervise the progress of the
trial, review information from other sources (such as
related trials), communicate the progress of the trial to
relevant parties (such as sponsors and funders) and ad-
vise on publicity and presentation of all aspects of the
trial [2]. The inclusion in TSCs of members who are in-
dependent of both the trial and its TMG is seen as crit-
ical in avoiding real or perceived conflict of interest or
bias [3] and protecting both trial participants and CIs
[4]. The MRC recommends that membership of a TSC
should include the CI, who is regarded as being non-
independent of the trial, an independent Chair and no
fewer than two other independent members [2]. While
non-independent members of the trial team can attend
TSC meetings, their role is solely to provide informa-
tion and clarification to independent TSC members.
However, there are apparent inconsistencies or ambigu-
ities in some of the guidance related to TSCs. According
to the MRC’s Guidelines for Good Clinical Practice, for
example, the TSC prioritises the rights, safety and well-
being of the trial participants over the interests of science
and society [2], yet its more recent guidance specifies that
trial supervision by the TSC is on behalf of the trial Spon-
sor and trial Funder [4]. Definitions of ‘independence’ as it
applies to trial oversight also vary. These include “not in-
volved directly in the trial other than as a member of the
TSC” [1], “independent of the investigators, their employ-
ing organisations, funders and sponsors” [4] and having
no stock ownership in any pharmaceutical company in-
volved, no frequent speaking engagements on behalf of
the intervention, no emotional involvement in the running
of the trial and not being employed in the same workplace
as major members of the trial team [3].
Previous qualitative research in the DAMOCLES pro-
ject examined the role of DMCs in overseeing trial data
collection procedures and advising TSCs [5], resulting in
the now widely used 2005 charter for DMCs [6, 7].
However, little attention has been given to the role and
function of TSCs and how guidance on TSCs such as
that produced by the MRC is applied within trial over-
sight [7]. Two recent studies have begun to consider
these questions [1, 7, 8]. A quantitative survey of 38 UK
clinical trials units [7] found that greater clarity is
needed regarding the relationship between a TSC and
the trial funder or sponsor and the extent of independ-
ence required from TSC members. Similarly, the report
of Harman et al. of an expert panel review on the role
and function of TSCs suggests that the nature of TSCs’
independence, the manner in which TSC members
should be appointed and to whom a TSC is responsible
are unclear [8]. These study designs, however, did not
allow in-depth exploration of the role of TSCs in prac-
tice. To complement these studies and inform future re-
visions of MRC guidance and TSC terms of reference,
we aimed to explore the role and valued attributes of
TSCs using a multi-perspective ethnographic design.
Methods
A cross-sectional ethnographic study was conducted,
using non-participant observation and interviews to ex-
plore the role and value of TSCs. Findings from observa-
tion of TSC and TMG meetings were triangulated and
integrated with findings from interviews with independ-
ent and non-independent TSC members, trial sponsors,
funders and CIs to give a rich, multi-perspective ac-
count. Our research is situated within a post-positivist,
minimally realist paradigm appropriate to applied health
services research [9].
Sample and setting
Based on the research team’s experience and expertise in
trials, we hypothesised that the role and value of TSCs
would be more clearly articulated in TSCs dealing with
challenging scenarios than in other trials. We therefore in-
cluded trials if they were currently experiencing a diffi-
culty, e.g. recruitment issues, protocol amendments or
deviations, participating centres experiencing problems,
early release of safety data, early publishing of data or rec-
ommendations from the DMC to stop recruitment. A sec-
ond inclusion criterion was having a TSC meeting planned
within the study period (March 2013 – January 2014).
Eight randomised trials meeting the criteria were pur-
posively selected to represent a range of clinical topics
(e.g. elderly care, cancer, mental health), healthcare set-
tings (primary and secondary care), interventions (e.g.
pharmaceutical and psychological) and oversight com-
mittee structures (e.g. dedicated TSC serving one trial or
‘umbrella’ TSC overseeing several trials). The sample
size of eight was chosen to enable in-depth fieldwork
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and analysis across a diverse range of trials. Trials were
identified through the UKCRC Registered Clinical Trials
Unit Network [10] and a major UK funder of trials. The
CTU Network nominated trials and approached trial
Chief Investigators (CIs) to invite inclusion of their trial.
In addition, the funder identified trials facing difficulties
and contacted the CIs with invitations to participate. CIs
interested in their trial being included contacted the re-
search team directly.
Purposive sampling was used to select independent
and non-independent TSC members with differing per-
spectives on and involvement in the selected trials. Inde-
pendent TSC members included TSC Chairs and non-
independent members included TMG members. Data
collection continued for each trial until data saturation
was reached; i.e. no new themes emerged during data
analysis [11]. Supplementary interviews were conducted
with a purposive selection of trial funder and spon-
sor representatives and CIs with experience of other
challenging trials to gain wider perspectives.
Data collection
All observational and interview data were collected by
the same researcher (AD), a qualitative researcher expe-
rienced in health services research.
Observational data
One TSC meeting was attended, observed and audio-
recorded for each trial, with prior consent from TSC
members. In addition, to provide a context for discus-
sions within TSC meetings, the researcher attended, ob-
served and audio-recorded relevant TMG meetings
during the study period. Detailed field notes were taken
during and after the meetings, guided by a standardised
observation schedule.
Interviews
TSC members were invited for interview by the relevant
trial CI or by the researcher approaching them directly
at meetings. Interviews were conducted before or after
the TSC meeting depending on participant availability
and preference. Supplementary interviews were con-
ducted with funder, sponsor and CI representatives
known to have differing opinions regarding the role and
value of TSCs, identified via snowball sampling [12]. All
interviews were conducted either face-to-face or by tele-
phone, depending on participant preference, and were
recorded and transcribed verbatim.
The semi-structured interview topic guides, formu-
lated on the basis of the literature regarding trial over-
sight and the research team’s expertise, are summarised
in Table 1.
Data analysis and rigour
Observational data (meeting recordings and field notes)
and interview data were analysed using thematic analysis
[13]. A preliminary analysis was conducted by the pri-
mary researcher (AD) alongside data collection, to en-
able data gathered earlier on to inform subsequent data
collection. Through a combination of deductive line-by-
line coding, based on the research aims, and inductive
analysis, an initial coding framework was developed
using techniques of constant comparison [14]. Members
of the research team (AS, AL, SM, GS and HC) read and
independently coded a sub-set of interview and meeting
transcripts and met monthly to review data analysis and
emerging findings. During the meetings the coding
frame was refined into broader categories and higher-
level recurring themes, and data within themes were
scrutinised for disconfirming and confirming perspec-
tives. Finally, a narrative summary of the findings which
integrated data from the interviews and observations
Table 1 Interview topic guides
Participant
group
Topics discussed in interviews
Chief
Investigator
The trial: History of the trial, details of the trial, current
stage, successes, current and anticipated challenges
TSC Chair The TSC: Frequency of meetings, composition of TSC,
reasons for selecting members, how Chair was selected
and role in meetings, nature of the group’s decision-
making and members’ involvement, examples of
actioned group recommendations, impact of TSC,
communication between TSC and TMG, relationship of
and communication between TSC and other trial
oversight committees, aspects of TSC that could be
improved, recommendations for other trials regarding
role of TSC
TSC members The trial: History of participation in the TSC, views
regarding composition of the group and frequency of
meetings, relationships with other members, value of
TSC meetings, TSC’s role in decisions regarding trial,
relationship of and communication between TSC, TMG
and other trial oversight committees
TSC meetings: Meeting organisation, Chair and
leadership of meeting, communication during meeting,
process of decision-making (positive aspects and
challenges/difficulties, own and others’ contributions to
decision-making), process of agreeing and assigning
actions, communication of actions to other groups/trial
personnel, how future TSC meetings could be
improved
Trial funder
representatives
Funders’ expectations and views of TSCs, process of
selecting TSC, examples of TSC working well, examples
where TSCs haven’t worked well, different models of
TSCs, role of TSC Chair, role of Patient and Public
Involvement (PPI), role of the trial funder, regulatory
bodies, recommendations regarding TSCs
Sponsor
representatives
Sponsors’ expectations and views of TSCs, role of
sponsor in trial, responsibilities of sponsor, relationship
between sponsor, TSC and funder, challenges faced by
trials, qualities of a TSC Chair, decision-making by a TSC,
value of TSCs
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was constructed (LS, AD). Triangulation attended to
areas of divergence and convergence in the datasets and
the different perspectives represented.
The research team represents a range of disciplines
and expertise: qualitative health researchers, trial
methodologists, statisticians and social scientists with
backgrounds in psychology, anthropology and health
services research. Several team members had experi-
ence of being on TSCs and were known to some of
the participants; however, the researcher who collected
data had no prior relationships with the participants.
One of the informants interviewed was a member of
the study team and is a co-author on this paper, but
was not involved in data analysis or interpretation. Re-
flexivity was fostered by the researcher taking detailed
field notes on the research process [15] and group dis-
cussion of the context of knowledge construction at
the monthly team meetings [16]. Data analysis was
managed in NVivo v.10, which helped ensure audit-
ability [17].
In presenting findings, data have been anonymised to
protect confidentiality. ID codes and trial number are
used to identify quotes from interviews. Observational
data from meeting recordings and field notes are dated,
stating trial number.
Results
Eight trials participated, all of which were currently
recruiting. Six eligible trials were approached via the
CTU Network; the CI of one of these refused to partici-
pate, as the Chair of the TSC did not want observers at
their first ever meeting, in which building relationships
was key. The five other trials participated. In addition, of
the 32 trial CIs contacted by the funder, five contacted
the researchers regarding the study. To fulfil our recruit-
ment target of eight trials, three of these were purpos-
ively selected to participate.
We observed and audio-recorded eight TSC meetings
and six TMG meetings, totalling 14 hours, 45 minutes.
Meetings ranged from 40 minutes to 2 hours in length.
We conducted 65 interviews with 51 individuals, who
were either members of the eight trials’ TSCs or TMGs or
were other relevant informants working in this field
(Table 2). No one approached refused to be interviewed.
Interviews ranged from 19 minutes to 2 hours, 28 minutes
(mean 58 minutes). The median number of interviews per
trial was 10, range 6–11. The ratio of independent to non-
independent members of TSCs interviewed for each trial
ranged from 1:2 to 1:6.
Two main themes with sub-themes emerged: the role
of the TSC (quality assurance and patient advocacy) and
valued attributes of TSC members (experience and
independence).
Roles of the TSC: scientific quality assurance and patient
advocacy
Scientific quality assurance
The overall role of the TSC was defined in terms of as-
suring the rigour and quality of trials; for example, giv-
ing “an independent and knowledgeable view” (05,
Sponsor representative, trials 1 and 2) of trial progress
to guide the trial towards analysis and publication. Par-
ticipants reported that to fulfil this role, the TSC had to
be able to objectively criticise the trial and hold the trial
team to account while also providing support and ensur-
ing criticism is constructive. Several interviewees (47,
Funder representative; 40, Senior trial manager, trial 7;
39, CTU Director, trial 7) used the phrase ‘critical friend’
to describe this role, while others emphasised the criti-
cising or challenging component of the role; 20, TMG
member, trial 4) labelled it ‘tough love’ (Table 3). One
TSC Chair (42, trial 8) saw the primary and ethically
correct role of an independent TSC as that of a ‘critical
advisor’ who would be willing to be a ‘non-friend’ and
give unpalatable advice when a trial faces difficulties.
During observations of TSC meetings, the central role
of the Chair in enabling the TSC to fulfil its quality as-
surance role was evident. The TSC Chair of trial 3, for
example, seemed to have less control of the proceedings
compared with other Chairs, taking the CI’s ”enthusias-
tic, optimistic” projections of recruitment at face value
and skipping items on the agenda to save time, which
meant key members of the trial team were not given a
voice (field notes, TSC meeting trial 3). In contrast, the
Chair of trial 8 (42, quoted in Table 3) dealt with chal-
lenges encountered during the trial by “giving time-
frames to see improvements” as well as advising about
possible solutions (field notes, TSC meeting trial 8).
However, independent members other than the Chair
also played an important role in maintaining scientific
rigour. The less experienced Chair of trial 7 had a
“dream team” with her of two experienced TSC indepen-
dents who provided “guidance and reassurance” to en-
sure difficult decisions regarding the trial’s future were
made and implemented successfully (field notes, TSC
meeting trial 7).
In addition, the model of the TSC and its fit with the
trial topic also influenced the ability of the TSC to fulfil
its quality assurance role. One of the TSCs in the study
was an ‘umbrella’ TSC which oversaw several trials, all
in cancer, and reviewed paperwork from eight trials in
the 2-hour TSC meeting observed. While the discus-
sion of each trial in this meeting was necessarily brief,
the reports submitted by each trial and circulated to
the group in advance were noted to be very detailed,
with the TSC Chair selecting key elements for discus-
sion. In field notes after the meeting the researcher
commented on the efficiency of this model where trials
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Table 2 Characteristics of interview participants
Participant ID Role Gender Trial(s) involved in (subject area),
where applicable
01 TSC Chair (Clinician) M 1, 2 (oncology)
02 Senior trial project lead M 1, 5 (oncology)
03 TSC coordinator #1 M 1, 2 (oncology)
04 TSC coordinator #2 F 1, 2 (oncology)
05 Sponsor representative F 1, 2 (oncology)
06 Sponsor representative M 1, 2 (oncology)
07 Trial manager F 1 (oncology)
08 CI F 2 (oncology)
09 Trial manager F 2 (oncology)
10 Trial manager M 3 (arthritis)
11 Senior statistician M 3 (arthritis)
12 Senior trial manager F 3 (arthritis)
13 Statistician M 3 (arthritis)
14 CI M 3 (arthritis)
15 TSC Chair (Clinician) M 3 (arthritis)
16 Trial manager F 4 (frailty)
17 TSC Chair (Methodologist) M 4 (frailty)
18 CI M 4 (frailty)
19 TMG Chair F 4 (frailty)
20 TMG member F 4 (frailty)
21 Trial manager F 5 (oncology)
22 Statistician F 5 (oncology)
23 CI M 5 (oncology)
24 Independent TSC member M 5 (oncology)
25 Independent TSC member M 5 (oncology)
26 Trial manager F 6 (urology)
27 Trial manager F 6 (urology)
28 Statistician M 6 (urology)
29 CI M 6 (urology)
30 TSC Chair (Clinician) M 6 (urology)
31 Independent TSC member M 6 (urology)
32 TMG member M 6 (urology)
33 Trial manager F 7 (psychology)
34 CI F 7 (psychology)
35 PPI Representative M 7 (psychology)
36 TSC Chair (Clinician) F 7 (psychology)
37 Independent statistician M 7 (psychology)
38 TSC member M 7 (psychology)
39 CTU Director F 7 (psychology)
40 Senior trial manager F 7 (psychology)
41 Trial manager F 8 (oncology)
42 Chair (Clinician) M 8 (oncology)
43 PPI representative F 8 (oncology)
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are of a similar nature. Those interviewed from the TSC
suggested that the umbrella model would not work well for
complex interventions or when the trial itself is complex:
Where it’s an adaptive trial, lots of different activities,
it might be better that we’ve got a TSC that adapts to
the trial, similarly if you got a number of different
trial groups involved… That’s one reason why you
wouldn’t want… to use an umbrella TSC every time.
The other is actually is the way that they engage: there
is a difference in the way they engage at the two hour
meeting, looking just at your trial… compared to a
meeting where they meet for 5 or 20 minutes.
(02, Senior trial project lead, trials 1 and 5)
The same respondent highlighted the benefits of the
umbrella model:
Those guys know their stuff, they know their way
around the trials pretty well and the issues come up
time and time again and they read the papers… There
are plusses and minuses of the umbrella approach and
the standing trial approach, I’d say. I’ve experience of
using both and I think they both work fairly well. (02,
Senior trial project lead, trials 1 and 5)
Table 2 Characteristics of interview participants (Continued)
44 Senior statistician M 8 (oncology)
45 Sponsor representative M 8 (oncology)
46 CI of other trial/member of TSCs M n/a
47 Funder representative M n/a
48 Sponsor representative M n/a
49 Funder representative F n/a
50 Senior statistician F n/a
51 Funder representative F n/a
Table 3 TSC as ‘critical friend’, provider of ‘tough love’ or ‘critical advisor’: exemplifying quotes
TSC as ‘critical friend’ The ideal function of the Trial Steering Committee [is to] act as a critical friend to the trial,
whereby they support the trial to some extent but then they do also ask the awkward
questions and hold them to account. (50, Senior statistician)
It was really important to have that external objective view of looking at the data
independently, but also, them being our critical friends, advising us and supporting us
through this… they’re there to support and help, they’re not just there to chastise. (40,
Senior trial manager, trial 7)
TSC as provider of ‘tough love’ [The role of a TSC] is, I think, tough love. (Laughter)… They’ve got to be on your side…
Because if you’ve got a TSC that’s against you, you might just as well hand the money
back now. (Laughter)… They’ve got to kind of be in your corner, but I think they've got to
be tough. (20, TMG member, trial 4)
If I don’t walk out of these meetings feeling like I’ve been given a bit of a kicking then they
haven’t done their job properly, that’s what they’re there to do … it’s their job to… point
out the things that we should be doing better. (23, CI, trial 5)
TSC as ‘critical advisor’ Interviewer: When I’ve asked that question of other people, they value the TSC being a
critical friend.
42, TSC Chair, trial 8: No, you can’t. It’s not a friend. A friend implies that the relationship
is a good one and always amicable. I wouldn’t hesitate to be a non-friend if I thought it
was wrong. Critical adviser – better. However, friend does imply that, “We’ll sit round the
table like friends and we’ll just discuss this and what we say will be okay for you.” So criticism;
yes, advice; yes. Friendship almost comes as a side issue.
Interviewer: Perhaps the friend bit was them implying that you need to be on their side?
42, TSC Chair: You’re not.
Interviewer: You’re not?
42, TSC Chair: No. You’re independent. So the words of wisdom that you give may be
words they don’t want to hear. Maybe we’re going to say, “Right, this trial needs to be
shut. It’s not working.” That’s happened three or four times it the last couple of years, in
other trials groups. It’s not a matter of cutting your losses. It’s a question of making sure
that it’s the ethically proper thing to do. So I’m very keen that meetings are conducted in
a friendly environment but we are there as advisers and critics.
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While the majority of respondents valued the TSC and
its contribution to the trial, one CI questioned the scien-
tific worth of the TSC. He acknowledged the value of
having a body to provide an ‘external check’ on trial
conduct, but in practice thought a TSC had very little
impact:
It seems, to a large extent, to be a rubber-stamping
process … an external group checking what you're
doing. But I'm not sure it makes a huge difference as
to the way the trial runs. (29, CI, trial 6)
The Chair also felt ambivalent about the value and
contribution of his TSC when the trial, he believed, was
running smoothly, and hence the TSC had little to
contribute:
I mean, there wasn’t very much on the agenda really,
it’s rather formulaic … because it’s going quite well
there isn’t a lot to say really. (30, TSC Chair, trial 6)
In contrast, members of the trial team overseen by this
TSC gave specific examples of how the independent
TSC members had aided the running of the trial:
So he (independent member) gave us some great input
on improving return rates because he’d worked on a
trial where they’d used text messages before. (28,
Senior statistician, trial 6)
The trial manager suggested a reason for this differ-
ence of opinion regarding the value of the TSC:
I think it is because I look at things on a day-to-day
level, whereas [CI] perhaps looks at things on a much
more broader basis…I value something like an increase
in the questionnaire return rate but he (CI) won’t see
it as being such a big thing as I do. (26, Trial manager,
trial 6)
These contrasting perspectives highlight the idea that
value is judged from a particular viewpoint: different
members of the trial team may value different forms of
input from a TSC. They also suggest that the role of the
TSC may change depending on how well a trial is doing,
from rubber-stamping when things are going well to be-
ing more critical and directive at other times.
Patient advocacy
An additional role of TSCs highlighted in the data
was that of patient advocacy. The responsibility of the
committee towards patients participating in trials was
emphasised in interviews and observed in meetings
(“patient value and safety… that’s the guiding thing”
(31, TSC Independent member, trial 6)). The role of
the TSC as ‘patient advocate’ (42, TSC Chair, trial 8;
45, Sponsor representative, trial 8) was evidenced in
phrases such as the patient being the ‘the only reason
we’re here’ (01, TSC Chair, trials 1 and 2) and the
‘end point in everything’, ‘the top of the pile’ (42, TSC
Chair, trial 8).
During the TSC meeting attended for trial 7, the
early stopping of recruitment several months earlier
was discussed, and the prioritisation of patient well-
being was clear:
37, Independent statistician, trial 7: That was really
the bit I was most interested in… what was going to
happen with the patients?
34, CI, trial 7: We did have worries. You remember we
set up telephone lines and all this. (Extract from TSC
meeting, trial 7)
What there was complete agreement about, was
concern for participants and the welfare of
participants in the trial. (39, CTU Director, trial 7)
The CI described therapeutic alternatives to the trial
intervention offered to participants who had not yet
started therapy, commenting that “the research thera-
pists were brilliant” (34, CI, trial 7, quoted from TSC
meeting). The team discussed a potential future publica-
tion on best practice in stopping trials of psychological
interventions, given their thorough approach to consid-
ering participant well-being.
As this demonstrates, patient advocacy was not distinct
from or in conflict with the scientific quality assurance
role of the TSC; rather, protecting patient well-being was
often perceived as intrinsic to assuring trial quality. How-
ever, an independent TSC member highlighted that the
roles of scientific quality assurance and patient advocacy
might be prioritised differently by TSC members:
I think in a philosophical way, [the role of the TSC]
is to protect the patient, and then the integrity of
the trial. I think that should be clear… it puts the
interest of the patient first and foremost. As an
independent, you are making sure that that is
observed. (37, Independent statistician, trial 7)
The participant differentiated ‘patient safety’ from ‘patient
well-being’, arguing that the latter is the remit of the TSC,
while the former is the responsibility of the DMC:
It’s to protect the patient… not just the safety, I think
the well-being… because strictly speaking, the safety of
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the patient is the exclusive reserve of the DMC. (37,
Independent statistician, trial 7)
Attributes of TSC members
For TSC members, particularly Chairs, to fulfil their roles,
two attributes emerged as essential: relevant experience
and impartiality through their independence. In particular,
both were seen to enhance the rigour of a trial and enable
quality assurance. However, while there was broad agree-
ment about the types of experience among TSC members
that were of value to a trial, there was less consensus
about the meaning of independence and how it could be
successfully implemented in practice.
Experience
Experience in three domains was valued in TSC mem-
bers: experience of running a trial, experience of sitting
on a TSC or DMC and experience or expertise in a par-
ticular clinical or methodological area.
Participants acknowledged the complexity of trials and
valued TSC members’ prior experience of involvement
in or running a trial. The value of experiential know-
ledge lay in being able to bring practical solutions to
problems from their own experience of conducting
trials:
A different view of the world, potentially, but also,
‘Well, when we tried that, it did not work, so we tried
this. Maybe you want to give this a try’ … To suggest
solutions from your past experience, your past
knowledge. (38, TSC Independent member, trial 7)
Experience of sitting on DMCs or TSCs was also
highly regarded by those who were active TSC mem-
bers. A TSC Chair who was relatively inexperienced ap-
preciated the knowledge and capability of the other
two independent members on the committee who were
experienced in this role, especially when the trial went
through a challenging period. Without their TSC ex-
perience, the Chair felt that her role would have been a
lot more stressful:
I probably would have asked permission, probably, to
seek advice elsewhere, but [the TSC independent
members] were extremely experienced and couldn’t
have been better. (36, TSC Chair, trial 7)
However, as this kind of advice and support are cur-
rently provided informally, some interviewees suggested
forming a national level advisory board that would ad-
vise in complex situations:
There could be some sort of scientific advisory board,
or methodological advisory board… So that when you
did hit the buffers, you know… there would be a
mechanism for saying, “Look we’re in difficult
circumstances here.”… You could actually have an
emergency TSC, of the great and the good, to descend
on the trial. (37, Independent statistician, trial 7)
The value of experience in specific clinical and meth-
odological areas was also evident in observational data.
In the observed meeting from trial 8, for example, inde-
pendent TSC members gave advice to the trial team re-
garding recruitment processes and outcome assessment
burden, and informed the less experienced Chair about
publication policies.
To ensure relevant experience among TSC members,
the Clinical Trials Unit Directors interviewed described
informal apprenticeship schemes within their units
where those with less trial oversight experience could
gain experience of TSCs and access relevant training.
There were different models of these apprenticeship
schemes, including junior staff taking an observer or
non-voting role on a TSC or gaining prior experience
on a DMC to improve understanding of committees’
respective roles and responsibilities:
The easier way to get experience of this, as trial
oversight, is as an observer or a non-voting member of
a TSC. Then you become a voting member of a TSC.
When you’ve got a broad range of experience, you then
come on a DMC. (39, CTU Director, trial 7)
When you’ve been on a DMC and had really difficult
decisions to make, you can kind of appreciate how
much is involved and usually how much racking of
brains has gone into it. If you’re aware of that from the
other side sitting on a TSC you think even harder
before you overturn the DMC decision. (44, Senior
statistician, trial 8)
Independent TSC members were in favour of a
more formal and national approach to the concept of
TSC apprenticeships, which could be incorporated
into the continuous professional development of re-
search staff.
There should be a national bureau or a national
register of TSC and DMC members. It should be part
of my academic obligation say, to take part in four a
year, or something… If we organised it on a national
level, and actually had proper training programmes,
on the back of that, so that more junior members of
staff could get trained up, and kind of get their pilot’s
licence — that’s the way to do it. (37, Independent
statistician, trial 7)
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Establishing a national apprenticeship system was seen
to safeguard the quality of future trial oversight commit-
tees and prevent a dearth of suitably experienced people
capable of protecting the participants of future trials.
Independence
Valued, but difficult to operationalise
Trial teams valued the independence of the external
members of the TSC, associating their distance from the
design and day-to-day management of the trial with
their ability to give impartial advice. In particular, the ab-
sence of a ‘vested interest’ was seen as essential in enab-
ling the TSC to fulfil its patient advocacy role:
If you have a vested interest in the outcome of the trial
as a clinician – trial management, we’ve invested in
the protocol, we want to deliver it … I would hope that
we would always have the same approach in thinking
about patients first, but I think it’s that assurance
really, they don’t have invested interest. (12, Senior
trial manager, trial 3)
One CI reflected on how independence provided a
valuable check on the emotional and intellectual invest-
ment of trial team members, which might put them at
risk of prioritising recruitment or early release of data
over patient welfare:
The independence was key, because at that time, I
would have done anything to not have the trial
stopped. Really, it was correct that it should have
been, as per Protocol. Now that things have calmed
down, you think, “That is how it should have been.”
(34, CI, trial 7)
The independence of TSC members was also valued
by sponsors and funders. Sponsors were conscious of
the wider community’s perception of the quality of a
trial. They valued independence as it provided a quality
kite mark that signalled to outsiders the ‘integrity’ (48,
Sponsor representative) of the trial:
For external purposes it’s important as well, just how
it’s perceived by people outside, I think that’s
important…for the rigour and for the integrity of the
trial. (48, Sponsor representative)
Funders particularly appreciated independent TSC
members during challenging times in the life of a
trial, such as when decisions about continuation of
the trial were needed. The independent TSC members
were considered crucial at such times, given potential
biases about trial viability among non-independent
members:
Obviously [for] those that have been involved in
developing the study … I think it’s quite difficult to
remain unbiased towards continuation of the study.
(49, Funder representative)
However, perspectives varied as to how ‘independence’
should be defined. Funder representatives were aware of
the difficulties of implementing independence, particu-
larly in the context of trials within in a specific clinical
area, in which the same individuals are involved in mul-
tiple roles:
From a tight knit [clinical] community the same
people that are either the chief investigators, serving
on a Trial Steering Committee, serving on our Peer
Review Committee, are the same people year after
year, you know… (49, Funder representative)
According to some funders’ requirements, independ-
ent TSC members should neither be from the same in-
stitution as any of the applicants or members of the trial
team, nor part of an institution where participants are
being recruited. The narrowness of this definition was
criticised due to both the difficulty of implementing it
and its potential threat to trial conduct. In multi-centre
trials involving many known experts in the field, inde-
pendent members were difficult to find; in the words of
one CI, it “really leaves you kind of short of places to
look” (29, CI, trial 6). In one trial, an independent mem-
ber had to resign from the TSC because they changed
jobs, disrupting trial oversight:
We got a new independent member because one of the
members … who’s actually been the one who’s made a
lot of the good suggestions about what we can do
about recruitment and so on… he’s moved here, and
somehow or other that’s now a conflict of interest, and
I think why? I mean, I still don’t know the bloke and
his expertise hasn’t changed just because he’s moved
institution, but suddenly he can’t be an independent
member. (29, CI, trial 6)
Some participants argued that institutional affiliation
was less of a threat to independence than one’s relation-
ship (e.g. frequent collaborations) with the trial team.
While this was acknowledged by a Director within a fund-
ing body, he still maintained that employment in a separ-
ate institution is the key factor determining independence:
People are never a hundred per cent independent in
the sense that they’re often known to, and in fact
they’re nominated by the investigators themselves…
but they are nevertheless independent in a sense [that]
they’re not from the same institution and certainly
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aren’t co-applicants and grant holders on the same
study. (47, Funder representative)
Scientific quality of a study was considered at risk
when trial teams were required to approach ‘independ-
ent’ members outside the specific clinical area and/or
who lacked the detailed knowledge that may be helpful
to the trial. This could occur when existing experts were
judged to be too close to the trial or its team. The re-
quirement of independence thus came into tension with
the valued attribute of relevant experience:
It is difficult to describe the [disease x] clinical
community as anything other than a web… everyone’s
interconnected in some way… it’s a small world, so if
you want that experience, if you want people who
know the area, it’s going to be very difficult to get
people who aren’t in some way connected. (02, Senior
trial project lead, trials 1 and 5)
The [funder] fired me [from a DMC], on the basis that
by moving back to [city X], I was now at the
institution where one of the minor grant holders was…
If you insist on that independence, two things are
going to happen. First of all, almost by definition, you
are going to get someone who is out of the field.
However good they are, they’re not going to know
about this specific clinical area. Secondly, you run the
risk of just getting somebody who isn’t very good. (38,
TSC Independent member, trial 7)
‘Going native’ and the appointment of independent TSC
members
The funders interviewed expressed concerns about inde-
pendent TSC members losing their independence over
time through their engagement with the trial and the
non-independent members of the TSC. The term ‘going
native’ was used to describe their perception of a lessen-
ing of impartiality by independent TSC members who
became too close to the trial team. This was of disquiet
to funders, as they saw the TSC as potentially at risk of
colluding with the trial team, reducing the rigour of a trial:
We use the phrase “TSCs go native”, where they rather
forget that they’re there to provide the independent
function and…they change into more like the Trial
Management Group and see their role as, as there to
support the researchers. My own view is that that’s
unhelpful. (47, Funder representative)
Although there were no obvious examples of this in
the observational data, as mentioned above, TSC Chairs
varied in the extent to which they questioned trial team
members, with some accepting their reports at face
value and others exhibiting a more critical approach.
For independent TSC members, negotiating their role
in contributing expertise to a study, while also remaining
independent, could be challenging:
On the one hand, you don’t want to be completely
dogmatic about this… you see a car crash 100 yards
down the road, you don’t sit on your hands and say,
“Well I’m duty bound not to, you know, not to mention
this.” But on the other hand, you do have to be careful,
that you don’t roll your sleeves up and without really
realising it, change your role, from being an
independent trials team committee, to another organ
of the research team. (37, Independent TSC member,
statistician, trial 7)
The risk of loss of independence was reported to be a
prime motivator for funders seeking control over the ap-
pointment of external TSC members and the right to ap-
point new members. However, TMG and TSC members
expressed concerns about this arrangement, questioning
whose interests were being served in establishing the
TSC, the funder’s or patients’. Independent TSC mem-
bers and CTU Directors in particular thought that some
funders were increasing their control of governance of
the TSC while paying inadequate attention to the need
for the TSC to be independent from the funder. This
was described as shifting the focus away from quality as-
surance on ‘behalf of the funder’ towards ‘protecting the
purse’ of the funder:
One of the things, I think… that the [funder] needs to
grasp, is that it’s not about protecting their purse,
because there’s a danger with the way that the [funder]
is pushing it: the TSC is seen as protecting the funder
rather than holding everybody to account and working
to ensure that this is delivered on behalf of the funder.
It’s quite a subtle difference… Some TSC chairs, I
think, see themselves as closer to the funder than
others, and that’s another form of conflict of interest, if
you’re too close to the funder. That’s not acknowledged
at all. (39, CTU Director, trial 7)
For some respondents, the nature of the relation-
ship between funder and TSC was therefore critical
to the TSC’s ability to fulfil its patient advocacy role.
One independent member of a TSC argued that the
scientific community, not the funder, should appoint
experts to the TSC to uphold the interests of patients:
The TSC is supposed to be an independent
organisation, whereas [a Funding Director] now
has very definitely seen it as first and foremost
representing the funder’s interest. Now, I said to
him, “Look if you just take those letters that you
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are sending out to all the independents [TSC
members] that explains their role, just cross out
[funder’s name] and put in [pharmaceutical
company’s name], and it will make very
uncomfortable reading.” (38, TSC independent
member, trial 7)
Discussion
This study, the first to explore using qualitative methods
the role of TSCs in trials, demonstrates tensions and
ambiguities in the roles expected of a TSC and the attri-
butes valued of TSC members. Scientific quality assur-
ance and patient advocacy were identified as the primary
roles of the TSC. The quality assurance afforded by the
TSC was understood in subtly different ways, reflected
in characterisations of the TSC as a supportive ‘critical
friend’, a provider of ‘tough love’ or a ‘critical advisor’
not afraid to give unpalatable advice. In general, TSCs
were highly valued for the role they played in steering
trial conduct, although perceived value could differ
between people involved in different capacities in the
same trial.
In fulfilling the role of quality assurance, the attributes
of experience and independence were seen as critical.
Experience enabled TSC members to provide well-
informed advice; independence, to remain impartial and
balance the potential for biases in the trial team. How-
ever, we found that the requirements of experience and
independence could conflict. Operationalising funder
definitions of independence was difficult, particularly in
niche fields of expertise. Here, strict requirements of in-
dependence were perceived as potentially detrimental to
the running of a trial, preventing the recruitment of TSC
members with relevant experience and expertise. Inde-
pendence, and therefore quality assurance, was also re-
portedly threatened by TSC members ‘going native’ and
losing impartiality. This phenomenon motivated funders’
own selection of independent TSC members. However,
the propriety of this involvement by funders was de-
bated, with some seeing independence of the TSC from
the funder as critical to the TSC’s ability to fulfil its pa-
tient advocacy role.
Findings from this study have clear implications for re-
visions of the MRC’s guidance and terms of reference
for TSCs [1, 2]. The tensions we identified point to a
lack of clarity in existing guidance in the following areas:
1. The responsibility of the TSC: Is the TSC’s
primary responsibility to uphold the interests of
the funder/sponsor, patient, or both? If the latter,
then how should the needs of each be balanced?
If primary responsibility of the TSC is to the
patient, what does this mean for involvement of
the funder in trial governance?
2. The meaning of ‘independence’ in the context of a
TSC: How should ‘independence’ be operationalised,
particularly in narrow specialisms in which relatively
few people have relevant expertise and experience?
3. The selection of independent TSC members:
Related to item 1 above, what should the role of
the funder be in selecting TSC members? Can the
interests of patients be upheld if a funder is
involved in this choice?
We recommend a revised version of the MRC guid-
ance and terms of reference take into account the
current ambiguity and lack of clarity in these areas.
Clear guidance, standardisation of processes and trans-
parent decision-making in these areas are needed. The
development of consensus about the appropriate defin-
ition of independence and strategies for operationalising
this when establishing a TSC would contribute towards
achieving this. Recent MRC and NIHR guidance clearly
indicate a move towards the TSC acting on behalf of the
sponsor and funder [4], but debate is needed. Should the
TSC first and foremost represent sponsors’ and funders’
interests? Or should its role primarily be as an inde-
pendent organisation providing overall supervision of
the trial? Our study participants gave particular weight
to the ‘patient advocate’ role of the TSC, even above
their recognised role in ensuring trial integrity [18], and
differentiated between the responsibility of the DMC for
patient safety and the responsibility of the TSC for pa-
tient well-being. However, ensuring patient well-being is
not currently identified in the MRC Guidelines as one of
the key responsibilities of the TSC [2]. Updates to TSC
terms of reference should consider giving greater prom-
inence to the promotion of patient well-being during the
oversight process.
This study has strengths and limitations which should
be considered in interpreting the transferability of our
findings. We utilised multiple ethnographic methods,
which allowed an in-depth exploration of the role of
TSCs from several perspectives that would not be
possible using quantitative or single methods alone. In
particular, our observational data demonstrated how dif-
ferences in chairing styles impacted the ability of a TSC
to provide quality assurance and gave insight into how
the patient advocacy role of the TSC plays out in a TSC
meeting. The eight UK trials in our study are not repre-
sentative of all randomised trials: seven were funded by
one UK funder of trials and the other by a charity; trials
funded through other sources and in other countries
may face different issues. Furthermore, we selected trials
experiencing challenges, and believe this gave us added
insight into the role of TSCs. However, an interesting
area for future research would be to compare our find-
ings with the reported roles and value of TSCs in trials
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which are not undergoing such difficulties, as experi-
ences and opinions may differ.
Our findings support and add to the findings from the
expert panel of Harman et al. [8]. We found the nature of
independence to be a key ambiguity in the characterisa-
tion of TSCs. The experts in Harman’s study, like the re-
spondents in this study, raised the question of to whom
the TSC was primarily responsible and how this influ-
enced their independence. Ensuring relevant experience
and skills among TSC members was also raised in both
studies, suggesting that capacity building is an area that
requires attention as the field develops. Participants in our
study discussed informal apprenticeship schemes designed
to ‘train up’ less experienced staff who would become the
independent TSC members of the future. To ensure the
consistent training of potential independent TSC mem-
bers, a formal national apprenticeship scheme was sug-
gested. Such a scheme could work if the processes and
time required for apprentices to observe and reflect on
TSC meetings with appropriate mentors are clearly articu-
lated and factored into the funding of trials. The appren-
ticeship scheme would provide experiential ‘on-the-job’
training of TSC functioning, and not just classroom-based
teaching of particular skills (e.g. statistics).
We found that three types of experience among TSC
members were valued: experience of running a trial, ex-
perience of sitting on a TSC or DMC and experience or
expertise in a particular clinical or methodological area.
All three of these areas of experience were stated as re-
quirements of TSC members in a recent survey of regis-
tered CTUs [7]. However, this study provides further
insight as to why trial teams value these types of experi-
ence. Where TSC Chairs or independent members
lacked this experience, participants suggested that a na-
tional Advisory Board would be useful to advise inde-
pendent TSC members in complex situations, e.g. when
facing challenging decisions such as stopping a trial.
Further research is needed to grow the evidence base re-
garding trial oversight. In particular, the relationships be-
tween TSC members, the TMG and DMC, and the role of
the TSC Chair emerged as important in understanding
trial oversight in practice; the DAMOCLES project re-
ported similar findings in relation to DMCs [6]. Further
in-depth investigation in these areas is warranted. In
addition, it was beyond the scope of this paper to explore
the role of PPI representatives in trial oversight and con-
duct, and future research in this area is needed [19].
Conclusions
This qualitative study of the TSCs of eight clinical trials
facing challenges revealed that independent TSC mem-
bers provide impartial and informed advice to improve
scientific rigour and to act as trial participants’ advocates
to ensure their well-being. However, we found tensions
and ambiguities in the roles expected of TSCs and the
attributes valued of TSC members. In particular, the re-
quirements of both independence and experience could
conflict, impacting the quality assurance role of the TSC.
Although independence of TSC members is valued,
operationalising funders’ definitions of independence
can generate logistical issues. Concerns were raised re-
garding whose interests are served by funders’ criteria of
independence; in particular, funders’ selection of TSC
members was thought to have detrimental ramifications
for the TSC’s patient advocacy role. These findings
should be incorporated in revising guidance and terms
of reference for TSCs.
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